Equity Profile

ILMN

Illumina, Inc.

Health CareLife Sciences Tools & Services$29.1B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

$1.36

Revenue

Revenue figures will provide insight into the company's sales performance and demand for its products and services.

$1.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services. They focus on genetic sequencing technology, which plays a crucial role in personalized medicine and genomic research, making it a key player in the evolving health care landscape.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In Q1-2026, Illumina reported an EPS of $1.15, exceeding expectations by nearly 10%. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Illumina's upcoming earnings, expecting solid performance based on previous results.

Bull Case

If Illumina beats expectations again, it could signal strong demand for its products, potentially leading to a significant stock price increase.

Bear Case

Conversely, any disappointing results could raise concerns about market demand and competition, leading to a negative reaction in the stock.

Key Metrics to Watch

EPS

$1.36

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

Revenue

$1.1B

Revenue figures will provide insight into the company's sales performance and demand for its products and services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Illumina's EPS exceed the consensus estimate of $1.36?

A beat on EPS would reinforce the company's growth narrative and could lead to a positive stock reaction.

What are the revenue expectations compared to the consensus of $1.1B?

Revenue performance is crucial for understanding market demand and the company's ability to grow in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Illumina's growth potential due to its expanding market in genetic testing, which could drive higher-than-expected revenue.

Supporting Evidence

Illumina's recent product launches may not be fully reflected in analyst estimates.

The company's strong track record of beating EPS estimates suggests it could continue this trend.

Options pricing indicates a significant expected move, reflecting investor uncertainty about the results.

Key Risk

If revenue comes in significantly above $1.1B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be closely watched as they will indicate whether Illumina can maintain its growth trajectory amidst increasing competition.

Bull Confirmed If

An EPS of $1.40 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.29 would raise concerns about market competitiveness and demand.

Pre-Earnings Positioning

Options Market

Implied Move

±19.18%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats estimates, history suggests the stock could rise by around 1.42% on the following day, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of around 2.83% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive pressures in the genetic sequencing market.
3Insights into customer demand trends for Illumina's products.
4Guidance on future revenue growth and market expansion plans.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Illumina, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

EPS

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

$1.36

Revenue

Revenue figures will provide insight into the company's sales performance and demand for its products and services.

$1.1B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ILMN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+111.82%

Avg Stock Reaction

+1.42%

Last Quarter Recap

In Q1-2026, Illumina reported an EPS of $1.15, exceeding expectations by nearly 10%. The stock reacted positively, gaining over 5% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Illumina's upcoming earnings, expecting solid performance based on previous results.

Bull Case

If Illumina beats expectations again, it could signal strong demand for its products, potentially leading to a significant stock price increase.

Bear Case

Conversely, any disappointing results could raise concerns about market demand and competition, leading to a negative reaction in the stock.

Key Metrics to Watch

EPS

$1.36

Earnings per share is a critical measure of profitability and will indicate how well the company is managing its costs and generating income.

Revenue

$1.1B

Revenue figures will provide insight into the company's sales performance and demand for its products and services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Illumina's EPS exceed the consensus estimate of $1.36?

A beat on EPS would reinforce the company's growth narrative and could lead to a positive stock reaction.

What are the revenue expectations compared to the consensus of $1.1B?

Revenue performance is crucial for understanding market demand and the company's ability to grow in a competitive landscape.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Illumina's growth potential due to its expanding market in genetic testing, which could drive higher-than-expected revenue.

Supporting Evidence

Illumina's recent product launches may not be fully reflected in analyst estimates.

The company's strong track record of beating EPS estimates suggests it could continue this trend.

Options pricing indicates a significant expected move, reflecting investor uncertainty about the results.

Key Risk

If revenue comes in significantly above $1.1B, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be closely watched as they will indicate whether Illumina can maintain its growth trajectory amidst increasing competition.

Bull Confirmed If

An EPS of $1.40 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $1.29 would raise concerns about market competitiveness and demand.

Pre-Earnings Positioning

Options Market

Implied Move

±19.18%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant potential move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±19.2% while ILMN has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

41.8%

Calls (160K)P/C Ratio: 0.12Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Illumina beats estimates, history suggests the stock could rise by around 1.42% on the following day, confirming strong market demand.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline, with historical data indicating an average drop of around 2.83% following disappointing results.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches and their expected impact on revenue.
2Management's commentary on competitive pressures in the genetic sequencing market.
3Insights into customer demand trends for Illumina's products.
4Guidance on future revenue growth and market expansion plans.